DIZAL PHARMACEUTICAL CO., LTD. HKEX Listing Application Lapsed; Flagship Asset ZEGFROVY® Is the World’s Only Approved Small-molecule Targeted Therapy for EGFR Exon20ins-mutated Lung Cancer

NewTimeSpace News: Per information published on the HKEX official website, the Main Board listing application filed by Dizal (Jiangsu) Pharmaceutical Co., Ltd. on 23 January 2026 has lapsed after the six-month validity window expired. Goldman Sachs and Huatai International served as joint sponsors upon submission.

Founded in 2017 and spun out from AstraZeneca, Dizal Pharma is a commercial-stage biopharmaceutical enterprise. 

The Group owns two marketed medicines:ZEGFROVY^® (Sunvozertinib): The world’s only approved small-molecule targeted therapy for patients with EGFR exon 20 insertion mutation non-small cell lung cancer, launched in China and approved in the United States. It is the sole small-molecule agent recommended by the authoritative international NCCN Guidelines for this indication.Golidocitinib (brand name: Gaoruizhe^®): The world’s first and only approved JAK1 inhibitor for relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.